Lihui Guo works as a Research Fellow at Massachusetts General Hospital, Harvard University, he will focus on defining the mechanism of vaccine and antibody mediated protection against infectious diseases, such as Mycobacterium tuberculosis and other bacterial pathogens/diseases, Long Covid, Immune Aging, Sepsis, Pertuissis etc..

Lihui Guo received his PhD from University of Amsterdam. He conducted his PhD research under the supervision of Prof. Rene Lutter (ongoing collaboration), Marianna Bugiani, and Jan Willem W. Duitman in Experimental Immunology and Pulmonary Medicine from Amsterdam UMC. His research focuses on the role of IDO1/2 in infectious diseases such as Tuberculosis (TB), Tuberculous Meningitis (TBM), Fatal/severe COVID-19, and post-acute sequelae of SARS-CoV-2 infection (PASC, also called “long COVID”). In TB research, Lihui uses a range of models, including cell lines, murine, and zebrafish models, along with IHC staining of lung and brain tissues from TB patients. Lihui’s key focus is understanding how IDO1 activity in macrophages protects M. tuberculosis from antibiotic-induced killing, modulates apoptosis in infected macrophages, and facilitates M. tuberculosis translocation within macrophages, using electron microscopy (EM). In addition, Lihui has a strong interest in pathology, particularly Neutrophil Extracellular Traps (NETs) and the role of tryptophan metabolic stress in infectious diseases. Lihui is also exploring innovative treatments for Allergies (MMP-12) and Esophagogastric Cancer (EGC).